PriceTargets.com logo

Prothena - PRTA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $86.33
  • Forecasted Upside: 24.22%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$69.50 As of 06/9/2023 01:00 AM ET
▼ -0.45 (-0.64%)

This chart shows the closing price for PRTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prothena Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTA

Analyst Price Target is $86.33
▲ +24.22% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is $86.33, with a high forecast of $120.00 and a low forecast of $55.00. The average price target represents a 24.22% upside from the last price of $69.50.

This chart shows the closing price for PRTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Prothena. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/16/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/16/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/14/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/12/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/11/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/11/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/10/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/9/2023

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2023Cantor FitzgeraldBoost Target$98.00 ➝ $120.00Low
5/5/2023HC WainwrightBoost Target$75.00 ➝ $90.00Low
4/24/2023SVB LeerinkReiterated RatingOutperformLow
4/24/2023SVB SecuritiesInitiated CoverageOutperform$80.00Low
4/3/2023HC WainwrightReiterated RatingBuy$75.00Low
2/27/2023CitigroupLower TargetBuy$76.00 ➝ $72.00Low
2/24/2023HC WainwrightReiterated RatingBuy$75.00Low
1/27/2023Piper SandlerInitiated CoverageOverweight$94.00Low
12/21/2022Cantor FitzgeraldBoost TargetOverweight$91.00 ➝ $98.00Low
11/15/2022OppenheimerBoost Target$110.00 ➝ $120.00Low
11/4/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$52.00 ➝ $55.00Low
10/24/2022CitigroupBoost TargetBuy$65.00 ➝ $71.00Low
9/29/2022OppenheimerBoost TargetOutperform$100.00 ➝ $110.00Low
9/28/2022Royal Bank of CanadaBoost Target$45.00 ➝ $52.00Low
9/28/2022Bank of AmericaUpgradeNeutral ➝ Buy$45.00 ➝ $65.00Low
9/28/2022JMP SecuritiesBoost Target$50.00 ➝ $81.00Low
5/25/2022JMP SecuritiesLower TargetMarket Outperform$77.00 ➝ $50.00Medium
2/18/2022CitigroupLower Target$87.00 ➝ $73.00High
11/19/2021JMP SecuritiesInitiated CoverageOutperform$77.00High
9/30/2021Royal Bank of CanadaBoost TargetOutperform$59.00 ➝ $82.00Low
9/27/2021OppenheimerBoost TargetOutperform$90.00 ➝ $100.00Low
9/20/2021Fox-Davies CapitalInitiated CoverageOverweight$14.00Low
9/17/2021Cantor FitzgeraldBoost TargetOverweight$70.00 ➝ $103.00High
9/14/2021OppenheimerBoost TargetOutperform$82.00 ➝ $90.00High
8/9/2021OppenheimerBoost TargetOutperform$76.00 ➝ $82.00High
7/19/2021Royal Bank of CanadaBoost TargetOutperform$50.00 ➝ $59.00Medium
7/15/2021Cantor FitzgeraldBoost TargetOverweight$63.00 ➝ $70.00Medium
7/13/2021OppenheimerBoost TargetSell ➝ Outperform$54.00 ➝ $76.00High
7/13/2021HC WainwrightBoost TargetBuy$58.00 ➝ $75.00Medium
7/13/2021CitigroupBoost TargetBuy$57.00 ➝ $72.00Medium
6/25/2021BTIG ResearchBoost TargetBuy$29.00 ➝ $65.00High
6/18/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$12.00 ➝ $49.00High
6/11/2021Royal Bank of CanadaBoost TargetOutperform$28.00 ➝ $50.00Medium
6/10/2021HC WainwrightBoost TargetBuy$33.00 ➝ $58.00High
6/8/2021OppenheimerBoost TargetPositive ➝ Outperform$45.00 ➝ $54.00High
6/8/2021Cantor FitzgeraldBoost TargetOverweight$43.00 ➝ $62.00High
6/1/2021OppenheimerBoost TargetOutperform$40.00 ➝ $45.00High
5/26/2021CitigroupInitiated CoverageBuyHigh
5/12/2021OppenheimerBoost TargetOutperform$35.00 ➝ $40.00High
3/15/2021Jefferies Financial GroupBoost TargetBuy$30.00 ➝ $38.00High
3/2/2021OppenheimerReiterated RatingBuy$35.00Medium
2/26/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$14.00 ➝ $28.00Medium
2/12/2021Jefferies Financial GroupUpgradeHold ➝ Buy$15.00 ➝ $30.00Low
2/4/2021HC WainwrightBoost TargetBuy$22.00 ➝ $33.00Low
2/2/2021OppenheimerBoost TargetOutperform$25.00 ➝ $35.00Low
2/2/2021BTIG ResearchUpgradeNeutral ➝ Buy$29.00Low
12/10/2020OppenheimerBoost Target$20.00 ➝ $25.00Low
12/7/2020HC WainwrightInitiated CoverageBuy$22.00Low
10/21/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$20.00 ➝ $24.00High
9/13/2020OppenheimerReiterated RatingBuy$18.00High
7/8/2020OppenheimerUpgradeMarket Perform ➝ Outperform$16.00High
5/13/2020OppenheimerReiterated RatingHoldHigh
5/10/2020NomuraReiterated RatingBuy$19.00High
4/23/2020OppenheimerReiterated RatingHoldLow
1/1/2020Nomura SecuritiesReiterated RatingBuy$19.00Low
12/22/2019Evercore ISIReiterated RatingBuy$14.00High
11/27/2019Evercore ISIUpgradeIn-Line ➝ OutperformLow
11/19/2019Evercore ISIUpgradeIn-Line ➝ Outperform$14.00High
5/31/2019BarclaysReiterated RatingSell$9.00Low
5/16/2019Cantor FitzgeraldReiterated RatingOverweightHigh
3/4/2019Cantor FitzgeraldInitiated CoverageOverweight$13.77High
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/11/2018OppenheimerReiterated RatingHoldHigh
8/8/2018Cantor FitzgeraldReiterated RatingBuy$18.00Low
6/15/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$14.00 ➝ $18.00High
(Data available from 6/9/2018 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/11/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/11/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/10/2023
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/9/2023
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/11/2023
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/10/2023
  • 7 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
5/10/2023
  • 8 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/9/2023

Current Sentiment

  • 8 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Prothena logo
Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $69.50
Low: $68.72
High: $70.60

50 Day Range

MA: $62.57
Low: $48.26
High: $78.59

52 Week Range

Now: $69.50
Low: $21.06
High: $79.65

Volume

281,158 shs

Average Volume

478,777 shs

Market Capitalization

$3.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Prothena?

The following sell-side analysts have issued stock ratings on Prothena in the last twelve months: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, SVB Securities, and TheStreet.
View the latest analyst ratings for PRTA.

What is the current price target for Prothena?

9 Wall Street analysts have set twelve-month price targets for Prothena in the last year. Their average twelve-month price target is $86.33, suggesting a possible upside of 24.2%. Oppenheimer Holdings Inc. has the highest price target set, predicting PRTA will reach $120.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $55.00 for Prothena in the next year.
View the latest price targets for PRTA.

What is the current consensus analyst rating for Prothena?

Prothena currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTA will outperform the market and that investors should add to their positions of Prothena.
View the latest ratings for PRTA.

What other companies compete with Prothena?

Other companies that are similar to Prothena include Arrowhead Pharmaceuticals, Cytokinetics, Ultragenyx Pharmaceutical, Blueprint Medicines and ACADIA Pharmaceuticals. Learn More about companies similar to Prothena.

How do I contact Prothena's investor relations team?

Prothena's physical mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company's listed phone number is (531) 236-2500 and its investor relations email address is [email protected]. The official website for Prothena is www.prothena.com. Learn More about contacing Prothena investor relations.